UK implored to back COVID-19 IP waiver at WTO

The UK has been urged to back a proposed IP waiver related to COVID-19 treatments before the World Trade Organisation (WTO) by business leaders, academics, economists and trade unions.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

WTO reveals draft of COVID-19 IP waiver

5 May 2022 A proposal for the COVID-19 vaccine waiver has been prepared for approval by the wider members of the World Trade Organisation.

Biotechnology

Pandemic blues: the global approach to COVID-related IP

20 January 2022 While the effort to secure greater vaccine and treatment equality via an IP waiver is admirable, it could stifle innovation and create long-term problems, say Matthew Howell and Lauren Griffin of Alston & Bird.

Asia

COVID-19: Protection of IP for AI tools

1 September 2020 As AI becomes a crucial weapon in the battle against the global pandemic, companies in the field need to ensure that their valuable IP is protected, as Mao Xiao Hong and Danny Yap of IPOS International explain.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK implored to back COVID-19 IP waiver at WTO

More on this story

Editor's picks

Editor's picks

More features